GlycoNet Integrated Services, a pan-Canadian glycomics facility, is one of the world’s leading glycomics facility to accelerate the discovery, development and commercialization of next-generation, sustainable, one-health innovations. The fully integrated national platform include 7 sites across Canada offering the following glycomics services:

 Glycan–Ligand Screening and Discovery
– Glycan Analysis
– Carbohydrate Synthesis
– Drug Discovery & High-Throughput Screening (HTS)
– Molecular Glycobiology & Glycoengineering

Our services, instruments, technologies and professional services are available to all researchers, from Canada and abroad, across academic, private, and government sectors. The facility’s scientific and technical personnel provides high-quality, high-throughput, and competitively priced products and services to all of its clients.

GlycoNet Integrated Services are funded by the Government of Canada through the Canada Foundation for Innovation – Major Science Initiatives Fund.

GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians.

GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

Why is glycomics important?

In 2020, 5 of the top 10 selling drugs are glycosylated and have a combined revenue of US$58B.
Global market for glycomics drugs to reach US$257B by 2028.

Network Investigators
Trained HQP
Funded Projects
Network Partners

Latest News

GlycoNet releases its 2022-2023 Corporate Report

The report encapsulates a comprehensive overview of the network’s achievements, breakthroughs, and collaborations in the field of glycomics throughout the past year.

Within the report, readers will gain insight into the cutting-edge research and advancements made by GlycoNet, a collaborative effort involving scientists, researchers, and experts from academia, industry, and government institutions. It delves into the pioneering discoveries in glycobiology, highlighting the innovative applications and technologies that have emerged within the network.

Senator Paula Simons gets the sweet scoop on GlycoNet and glycomics

Senator Paula Simons recently toured GlycoNet at the University of Alberta, exploring the realm of glycomics. The visit highlighted GlycoNet’s pivotal role in advancing glycomics and its transformative impact across One Health domains, underlined by discussions with GlycoNet’s CEO, Dr. Elizabeth Nanak.

The tour of cutting-edge labs showcased passionate researchers driving innovation in glycomics, and interactions with start-ups like 48Hour Discovery shed light on drug discovery advancements. This visit emphasized the value of such engagements, illustrating the shared commitment to a thriving future and the potential for collaborative efforts to elevate healthcare and nurture a diverse bioeconomy.

GlycoNet researchers develop ‘ice inhibitors’ to protect cells during cryopreservation

New compounds could open more opportunities for vital medical treatments, organ and tissue transplants, and reproductive medicine.

Network Members

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter


Scroll to Top